Chemotherapeutic agents doxorubicin and epirubicin induce a procoagulant phenotype on endothelial cells and blood monocytes

Journal of Thrombosis and Haemostasis

Volumn 7, Issue 4, 2009, Pages 619-626

  Swystun, L L ^a,b   Shin, L Y Y ^a   Beaudin, S ^a,b   Liaw, Patricia C ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b HENDERSON RESEARCH CENTRE   (Canada)

Author keywords

Chemotherapy; Endothelium; Monocytes; Thrombin generation; Thrombosis; Tissue factor

Indexed keywords

CASPASE 3; DISULFIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; ISOMERASE; METHOTREXATE; PHOSPHATIDYLSERINE; PROCOAGULANT; PROTEIN C; REACTIVE OXYGEN METABOLITE; THROMBIN; THROMBOPLASTIN;

ARTICLE; CELL ISOLATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EXPOSURE; ENDOTHELIUM CELL; ENZYME ACTIVITY; FLOW CYTOMETRY; HEMOSTASIS; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MONOCYTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; UMBILICAL VEIN; VASCULAR ENDOTHELIUM; WESTERN BLOTTING;

ANTIBIOTICS, ANTINEOPLASTIC; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CELLS, CULTURED; DOXORUBICIN; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; EPIRUBICIN; HUMANS; MONOCYTES; PHENOTYPE; PLASMA; THROMBOPHILIA;

EID: 63049125016     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2009.03300.x     Document Type: Article

References (33)

1. Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 2005; 6: 401-10.
2. Shen VS, Pollak EW. Fatal pulmonary embolism in cancer patients: Is heparin prophylaxis justified? South Med J 1980; 73: 841-3.
3. Ambrus JL, Ambrus CM, Mink IB, Pickren JW. Causes of death in cancer patients. J Med 1975; 6: 61-4.
4. Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 1983; 62: 14-31.
5. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991; 9: 286-94.
6. Clahsen PC, van de V, Julien JP, Floiras JL, Mignolet FY. Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study. J Clin Oncol 1994; 12: 1266-71.
7. Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MD, Hryniuk W, De Pauw S. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988; 318: 404-7.
8. Goodnough LT, Saito H, Manni A, Jones PK, Pearson OH. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients. Cancer 1984; 54: 1264-8.
9. Robert J, Vrignaud P, Nguyen-Ngoc T, Iliadis A, Mauriac L, Hurteloup P. Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer. Cancer Treat Rep 1985; 69: 633-40.
10. Bramwell VH, Morris D, Ernst DS, Hings I, Blackstein M, Venner PM, Ette EI, Harding MW, Waxman A, Demetri GD. Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma. Clin Cancer Res 2002; 8: 383-93.
11. Fracasso PM, Blum KA, Ma MK, Tan BR, Wright LP, Goodner SA, Fears CL, Hou W, Arquette MA, Picus J, Denes A, Mortimer JE, Ratner L, Ivy SP, McLeod HL. Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar. Br J Cancer 2005; 93: 46-53.
12. Danesi R, Innocenti F, Fogli S, Gennari A, Baldini E, Di Paolo A, Salvadori B, Bocci G, Conte PF, Del Tacca M. Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients. Br J Clin Pharmacol 2002; 53: 508-18.
13. Paredes N, Xu L, Berry LR, Chan AK. The effects of chemotherapeutic agents on the regulation of thrombin on cell surfaces. Br J Haematol 2003; 120: 315-24.
14. Reigner B, Watanabe T, Schuller J, Lucraft H, Sasaki Y, Bridgewater J, Saeki T, McAleer J, Kuranami M, Poole C, Kimura M, Monkhouse J, Yorulmaz C, Weidekamm E, Grange S. Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer. Cancer Chemother Pharmacol 2003; 52: 193-201.
15. Stephenson DA, Toltl LJ, Beaudin S, Liaw PC. Modulation of monocyte function by activated protein C, a natural anticoagulant. J Immunol 2006; 177: 2115-22.
16. Nishibe T, Parry G, Ishida A, Aziz S, Murray J, Patel Y, Rahman S, Strand K, Saito K, Saito Y, Hammond WP, Savidge GF, Mackman N, Wijelath ES. Oncostatin M promotes biphasic tissue factor expression in smooth muscle cells: Evidence for Erk-1/2 activation. Blood 2001; 97: 692-9.
17. Wheeler HR, Geczy CL. Induction of macrophage procoagulant expression by cisplatin, daunorubicin and doxorubicin. Int J Cancer 1990; 46: 626-32.
18. Walsh J, Wheeler HR, Geczy CL. Modulation of tissue factor on human monocytes by cisplatin and adriamycin. Br J Haematol 1992; 81: 480-8.
19. Bach RR. Tissue factor encryption. Arterioscler Thromb Vasc Biol 2006; 26: 456-61.
20. Damrot J, Nubel T, Epe B, Roos WP, Kaina B, Fritz G. Lovastatin protects human endothelial cells from the genotoxic and cytotoxic effects of the anticancer drugs doxorubicin and etoposide. Br J Pharmacol 2006; 149: 988-97.
21. Santucci L, Mencarelli A, Renga B, Pasut G, Veronese F, Zacheo A, Germani A, Fiorucci S. Nitric oxide modulates proapoptotic and antiapoptotic properties of chemotherapy agents: The case of NO-pegylated epirubicin. FASEB J 2006; 20: 765-7.
22. Versteeg HH, Ruf W. Tissue factor coagulant function is enhanced by protein-disulfide isomerase independent of oxidoreductase activity. J Biol Chem 2007; 282: 25416-24.
23. Wolberg AS, Monroe DM, Roberts HR, Hoffman MR. Tissue factor de-encryption: Ionophore treatment induces changes in tissue factor activity by phosphatidylserine-dependent and -independent mechanisms. Blood Coagul Fibrinolysis 1999; 10: 201-10.
24. Penn MS, Patel CV, Cui MZ, DiCorleto PE, Chisolm GM. LDL increases inactive tissue factor on vascular smooth muscle cell surfaces: Hydrogen peroxide activates latent cell surface tissue factor. Circulation 1999; 99: 1753-9.
25. Woodley-Cook J, Shin LY, Swystun L, Caruso S, Beaudin S, Liaw PC. Effects of the chemotherapeutic agent doxorubicin on the protein C anticoagulant pathway. Mol Cancer Ther 2006; 5: 3303-11.
26. Bates SM, Weitz JI. The status of new anticoagulants. Br J Haematol 2006; 134: 3-19.
27. Pendurthi UR, Ghosh S, Mandal SK, Rao LV. Tissue factor activation: Is disulfide bond switching a regulatory mechanism? Blood 2007; 110: 3900-8.
28. Ma L, Francia G, Viloria-Petit A, Hicklin DJ, du Manoir J, Rak J, Kerbel RS. In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: Modulation by lower-dose chemotherapy. Cancer Res 2005; 65: 5365-73.
29. Lechner D, Kollars M, Gleiss A, Kyrle PA, Weltermann A. Chemotherapy-induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity. J Thromb Haemost 2007; 5: 2445-52.
30. Muller I, Niethammer D, Bruchelt G. Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity (review). Int J Mol Med 1998; 1: 491-4.
31. Santucci L, Mencarelli A, Renga B, Pasut G, Veronese F, Zacheo A, Germani A, Fiorucci S. Nitric oxide modulates proapoptotic and antiapoptotic properties of chemotherapy agents: The case of NO-pegylated epirubicin. FASEB J 2006; 20: 765-7.
32. Cattaneo M. Hyperhomocysteinemia and venous thromboembolism. Semin Thromb Hemost 2006; 32: 716-23.
33. Fisgin T, Yarali N, Kara A, Bozkurt C, Birgen D, Erten U, Duru F. Hemostatic side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol 2004; 21: 77-83.